you have been injured as a result of the pharmaceutical drug Lotronex,
click here to get a free case evaluation.
Lotronex (alosetron hydrochloride, a Glaxo Wellcome product) was
initially approved by the FDA on February 9, 2000 for the treatment
of Irritable Bowel Syndrome (IBS). IBS is a common and debilitating
digestive disorder that afflicts an estimated 15% of the U.S. population,
mostly women. IBS causes lower abdominal pain and discomfort and
irregular bowel habits such as diarrhea or constipation.
approval and June 1, 2000 the FDA received seven reports of serious
complications of constipation and reports of ischemic colitis. These
resulted in hospitalizations, and surgical procedures.
November 28, 2000 Glaxo announced that it would voluntarily withdraw
Lotronex from the market.
you have been injured as a result of the pharmaceutical drug such
as Lotronex, click here to get a free